<DOC>
	<DOC>NCT02798211</DOC>
	<brief_summary>To demonstrate that the efficacy of secukinumab 300 mg at Week 16 is superior to placebo in adult patients with active PsA based on the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response.</brief_summary>
	<brief_title>Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Male or nonpregnant, nonlactating female patients at least 18 years of age Diagnosis of PsA classified by CASPAR criteria and with symptoms for at least 6 months with moderate to severe PsA who must have at Baseline ≥3 tender joints out of 78 and ≥3 swollen out of 76 (dactylitis of a digit counts as one joint each) Rheumatoid factor and/or antiCCP antibodies negative at screening A target skin psoriatic lesion and a PASI score of 1 or greater Chest Xray with evidence of ongoing infectious or malignant process Patients who ever received biologic immunomodulating agents including those targeting TNFα, IL6 and IL12/23 investigational or approved</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PsA, ACR, CASPAR</keyword>
</DOC>